Does RIPRETINIB Cause Product packaging quantity issue? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Product packaging quantity issue have been filed in association with RIPRETINIB (QINLOCK). This represents 0.1% of all adverse event reports for RIPRETINIB.
5
Reports of Product packaging quantity issue with RIPRETINIB
0.1%
of all RIPRETINIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Product packaging quantity issue From RIPRETINIB?
Of the 5 reports, 2 (40.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIPRETINIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does RIPRETINIB Cause?
Fatigue (582)
Alopecia (517)
Extra dose administered (357)
Death (356)
Underdose (345)
Nausea (292)
Drug ineffective (291)
Disease progression (290)
Hospitalisation (280)
Neoplasm progression (263)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which RIPRETINIB Alternatives Have Lower Product packaging quantity issue Risk?
RIPRETINIB vs RISANKIZUMAB
RIPRETINIB vs RISANKIZUMAB-RZAA
RIPRETINIB vs RISDIPLAM
RIPRETINIB vs RISEDRONATE
RIPRETINIB vs RISEDRONIC ACID